Showing results (801-810 of 991) with videos related to

Sort By:
Pageof 100
Frontiers in Microbiology|February 10, 2016
Temperature-Dependent Gentamicin Resistance of Francisella tularensis is Mediated by Uptake ModulationKathleen Loughman, Jesse Hall, Samantha Knowlton, et al.
Cancers|December 24, 2021
Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory StudyRianne D W Vaes, Kobe Reynders, Jenny Sprooten, et al.
Bioorganic & Medicinal Chemistry Letters|August 29, 2016
Indole-based allosteric inhibitors of HIV-1 integrasePratiq A Patel, Nina Kvaratskhelia, Yara Mansour, et al.
Nuklearmedizin. Nuclear Medicine|September 22, 2015
Concordance in the interpretation of PET after chemotherapy in advanced stage Hodgkin lymphomaC Kobe, G Kuhnert, H Haverkamp, et al.
European Radiology|July 30, 2024
Safety and efficacy of percutaneous arterial port Implantation for Hepatic Arterial Infusion ChemotherapyLouis Meyblum, Matthieu Faron, Frédéric Deschamps, et al.
Lung Cancer (Amsterdam, Netherlands)|April 6, 2013
Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinibM Bos, M Gardizi, H U Schildhaus, et al.
Scientific Reports|March 30, 2018
Caffeine Augments Anesthesia Neurotoxicity in the Fetal Macaque BrainKevin K Noguchi, Stephen A Johnson, Francesca M Manzella, et al.
Plos Pathogens|October 17, 2012
De novo GTP biosynthesis is critical for virulence of the fungal pathogen Cryptococcus neoformansCarl A Morrow, Eugene Valkov, Anna Stamp, et al.
European Journal of Haematology|August 30, 2023
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trialLutz van Heek, Jasmin Weindler, Claudia Gorniak, et al.
The Prostate|April 18, 2022
Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimensKobe C Yuen, Ben Tran, Angelyn Anton, et al.
Pageof 100